Advocacy intelligence hub — real-time data for patient organizations
Transposon Therapeutics, Inc. — PHASE2
Megace: FDA approved
Treatment of anorexia, cachexia, or an unexplained significant weight loss in patients with a diagnosis of acquired immune deficiency syndrome.
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Megace
Bristol-Myers Squibb Pharmaceutical Research Institute
Megace
(Megestrol acetate)Orphan drugBristol-Myers Squibb Pharmaceutical Research Institute
Adeline Vanderver, MD
Children's Hospital of Philadelphia
📍 Los Angeles, California
Stéphane BLANCHE, MD,PhD
Hôpital Necker - Enfants Malades Public Hospitals of Paris
Yanick Crow
University of Edinburgh
Nicholson Modesti
Children's Hospital of Philadelphia
Davide Tonduti
V. Buzzi Children's Hospital
Simona Orcesi
University of Pavia